To determine the influence of cell cycle-specific agents on primate hematopoiesis and fetal hemoglobin production, two juvenile cynomolgus monkeys (Macaca fascicularis) were repeatedly bled to maintain their hemoglobins at -6.5 g/dl and fetal hemoglobin levels at 3-5%. Six separate 5-d courses of hydroxyurea at 100 mg/kg per d were then administered over the next 200 d while phlebotomy was continued. These courses of hydroxyurea progressively raised the fetal hemoglobin levels to 17 and 18%, respectively. The drug had very little effect on the frequency of immature erythroid progenitors (BFU-E) in the bone marrow, but caused a marked reduction in the frequency of later progenitors (CFU-E) and a transient fall in the reticulocyte count. Following the courses of hydroxyurea, the number of F cells and the fetal hemoglobin level fell to base line over a period of 4 wk. Two control animals which were not phlebotomized showed no detectable increase in F cells or fetal hemoglobin when treated with the same regimen of hydroxyurea.
Introduction
We have previously reported that a single course of hydroxyurea at 100 mg/kg per d for 5 d markedly increases fetal hemoglobin production in Macaca fascicularis with hemorrhagic anemia (1) . In that report and elsewhere, we (2) and others (3) suggested that the increase in fetal hemoglobin induced by hydroxyurea and other cell cycle-dependent, phase-specific cytotoxic drugs might be due to preferential destruction of mature erythroid progenitor cells (CFU-E)' and precursors.2 This would be followed by replacement of the marrow erythroblast pool with cells immediately derived from less mature progenitors in which the fetal hemoglobin synthesis program is retained (4) . This proposed switch of the origin of erythroid precursors failed, however, to account for the very rapid increment of fetal hemoglobin and F cells and the lack of reticulocytopenia following treatment of experimental animals and patients with such agents (5) (6) (7) .
Here, we examine the effects of cell cycle-dependent, phasespecific drugs on HbF production in a simian model in more detail. First, we evaluated the effects of repeated courses of hydroxyurea, an S phase-specific drug, on fetal hemoglobin synthesis in order to define the potential for its practical application in the treatment of patients with hemoglobinopathies. Second, we measured the impact of hydroxyurea on reticulocyte production and on CFU-E and immature erythroid progenitors (BFU-E) and compared these effects to those exerted by 5-azacytidine, another S phase-specific agent. Finally, we investigated the relationship of the cell cycle-phase specificity of drugs to their influence on fetal hemoglobin production by evaluating the effects of vinblastine, an inhibitor of mitosis active in the M, rather than the S phase of the cell cycle. The results of these experiments show that, in this simian model, transient reduction of CFU-E and depression of reticulocyte production by cytotoxic agents does not itself lead to stimulation of fetal hemoglobin production. Optimal response is scheduledependent requiring a course of daily administration of S or M phase-specific drug for several days and occurs only in animals with accelerated erythropoiesis. The response is regularly associated with recovery of reticulocytosis following its suppression by drug administration.
Methods
Animal care. The juvenile M. fascicularis used in this study were maintained in accordance with the guidelines of the Committee on Animals of the Harvard Medical School and those prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources (8). Two animals were regularly phlebotomized to maintain hemoglobins at -6.5 g/dl and received parenteral cyanocobalamin, folic acid, and iron dextran as previously described (2) . Two additional animals were maintained as above but were not bled.
Courses of hydroxyurea were administered via a nasogastric tube under ketamine anesthesia as single doses daily for up to 5 d. 5 (1) .
Erythroid progenitor cell assays. To investigate the effects of drugs on mature erythroid progenitor cells, the ratio of CFU-E/BFU-E in 10 cells was established. This obviated inherent variability of the recovery of marrow low density cells, a variability that would be expected to be particularly noticeable following the administration of cytotoxic drugs. CFU-E were cultured in a plasma clot assay, as previously described (9) , using I U/ml of Step III Connaught erythropoietin. The CFU-E-derived colonies were scored on day 3. The plasma clot assay was utilized because its plating efficiency for CFU-E-derived colonies was three to five times that of the methyl cellulose assay.
BFU-E were cultured in a methylcellulose assay (10), again using 1 unit/ml of erythropoietin. BFU-E-derived colonies were scored at day 10 . For detection of the colonies derived from these progenitors, the methyl cellulose assay proved distinctly superior, providing more and larger colonies than those observed in the plasma clot assay. Low density bone marrow cells were plated at different cell concentrations ranging between 1.24 X 104 and 2.5 X 105/ml to ensure that a maximal cloning efficiency was obtained. In general, optimal growth was obtained between 1.5 X 104 cells and 2 X l0 cells/ml in the plasma clot assay, and 2.5 X 104 cells and 1 X l0 cells/ml in the methylcellulose assay.
Results
Effects ofhydroxyurea in unbled animals. To evaluate whether hydroxyurea has a direct effect on fetal hemoglobin production in the nonanemic state, the drug was administered daily at a dose of 100 mg/kg per d for 5 d to two unbled monkeys with completely normal hematopoiesis. No effect on fetal hemoglobin or F cell production was detected (data not shown).
Effects ofphlebotomy. Repeated phlebotomy totalling -100 ml/wk maintained the hemoglobin at -6.5 g/dl in two monkeys throughout the nearly 300 d of this study. In the absence of drug administration, this caused a reticulocytosis of -18% in animal I and 20% in animal II (Fig. 1) . These base-line values rose to -24 and 30%, respectively, as the study progressed (Fig. 1 ).
Fetal hemoglobin production by BFU-E-derived colonies. To determine the potential fetal hemoglobin program of primitive erythroid progenitor cells in this simian species, peripheral blood BFU-E were cultured in methylcellulose. This was done after phlebotomy had been started, but before any drug therapy commenced. BFU-E-derived colonies were plucked at 12 d when they appeared well hemoglobinized, and a lysate of the pooled colonies was subjected to electrophoresis in a Triton-urea gel. Densitometry of the stained gel revealed that the percentage of fetal hemoglobin comprised 39% of the total hemoglobin in the BFU-E-derived colonies of animal I and 56% with respect to animal II (data not shown). These values are very much higher than those found in man (11) , but are similar to those described previously in the Rhesus monkey (4) and in the baboon (12).
Effects of the initial doses of hydroxyurea on fetal hemoglobin production. As previously reported (1), hydroxyurea administration was instituted 62 d after regular phlebotomies Effect of hydroxyurea on other hematological parameters.
The 5-d hydroxyurea courses at 100 mg/kg per d led to an immediate fall in the neutrophil count, often apparent by the third day of therapy. Nadirs of 300 granulocytes/Al were occasionally observed, but it must be noted that the neutrophil count in this species is lower than that of humans and varies greatly from day to day. Equally low neutrophil values were observed sporadically during the control phlebotomy period. Neutrophil recovery to the desired 700 per microliter was also variable, occurring between 7 and 30 d following cessation of treatment. There were no infectious complications throughout the period of this study and both animals maintained their body weights.
The hydroxyurea therapy also caused a significant fall in the reticulocyte count. This fall was immediate and of very brief duration (Fig. 1) Fig. 3 . Similar progenitor cell perturbations were produced by both drugs, a marked depression of CFU-E relative to BFU-E. The changes in CFU-E/BFU-E ratios were very similar, though more pronounced, than those detected by Torrealba-de Ron and coworkers (3) in this setting.
Effects of vinblastine. Since both hydroxyurea and 5-azacytidine exerted similar influences on erythropoiesis and HbF production, we chose to examine whether such effects were characteristic of other cell cycle-dependent agents. We therefore decided to study the effects of vinblastine, a drug which is active in the M phase rather than the S phase of the cell cycle (13) . More than 4 wk after any previous treatment, and with the F cells and HbF at base line, the animals received 0.4 mg/kg of vinblastine as a single dose. Though all of the erythrokinetic effects of vinblastine were identical to those exerted by hydroxyurea, including the fall in reticulocyte production and marrow CFU-E to BFU-E ratio ( Fig. 3 and Table I ), there was no response of either F cell production or fetal hemoglobin in either animal (Fig. 2 B) . We then repeated a 5-d course of hydroxyurea in both animals to be certain that they remained capable of a fetal hemoglobin response. The results (Fig. 2 C) and HbF from 2 to 12% in animal I (Fig. 4) . The increase was less impressive in animal II in which inadvertent extravasation of vinblastine into subcutaneous tissues occurred. The increase in F cell response persisted for days in both experimental animals. These findings prompted an examination of vinblastine in combination with hydroxyurea. Two different schedules of drug administration were employed (Fig. 5) . In the first experiment, vinblastine was given concurrently with the first dose of a 5-d course of hydroxyurea (Fig. 5 A) . The magnitude of the F cell response was markedly augmented in comparison to that observed with hydroxyurea alone (Fig. 2 C) . There was also augmentation of the fetal hemoglobin response although this was less pronounced. In a second separate experiment, performed after full recovery from the first, each animal was given vinblastine on the final day of the 5-d course of hydroxyurea (Fig. 5 B) . Reticulocytopenia was severe and prolonged.
The F cell response was no greater than that produced by hydroxyurea alone but the onset and peak of the response were delayed markedly. They occurred 4-5 d later than following administration of either hydroxyurea or 5-azacytidine alone. Furthermore, the HbF per F cell was considerably higher when vinblastine was given at the end rather than at the beginning of the hydroxyurea course.
Finally Letvin, manuscript in preparation). Two additional S phase agents, cytosine arabinoside (14) and 5-azadeoxycytidine (15), 2002 Letvin, Linch, Beardsley, McIntyre, Miller, and Nathan have each been reported to produce increases in F cells and total fetal hemoglobin very similar to those reported here. Dose and schedule of administration of drugs are obviously critical. Neither a single dose of the hydroxyurea at 100 mg/ kg nor a 5-d course at 50 mg/kg were effective. Our studies of vinblastine not only emphasize the critical influence of dose and schedule but also direct our attention to the mode of action of these drugs on the HbF response. Vinblastine given as a single intravenous bolus at a dose that is at least twice the highest dose usually recommended for humans had an effect on erythropoiesis that was identical to that observed after 5 d of hydroxyurea administration at 100 mg/kg per d. There was a prompt decrease in reticulocyte production and in the frequency of CFU-E in the marrow, but, in contrast to the effects of hydroxyurea, there was no discernible influence on F cell production during the recovery phase. These data demonstrate that limited doses of cytotoxic drugs that transiently arrest reticulocyte production and renewal of late erythroid progenitors do not necessarily produce an F cell response. More severe and prolonged inhibition of reticulocyte production and late progenitors seems to be required. This conclusion is supported by the fact that whereas a single large dose of vinblastine was without effect on the F cell response, a 5-d course of vinblastine at a standard daily dose did induce an F cell response during the recovery phase. Furthermore, a single dose of vinblastine in combination with a single dose of hydroxyurea also produced measurable stimulation of F cell production though neither were effective alone. Further evidence that the length and severity of druginduced depression of erythroblast (and hence, reticulocyte) production from mature progenitors predicts the extent to which F cells will emerge during recovery in this model was gathered from studies of combinations of a single bolus of vinblastine with a 5-d course of hydroxyurea. The combination was more effective than either drug alone. The synergistic effect was particularly interesting when vinblastine was given at the end of a 5-d course of hydroxyurea. Though the onset of recovery of reticulocytes and F cells was retarded, the vinblastine-induced delay of entry into the M phase led to substantially higher accumulations of HbF in the F cells that were ultimately produced. Perhaps the enforced delay permitted the accumulation of larger amounts of gamma messenger RNA in the recovering erythroid cells.
Though a single unifying theory of the mode of action of these cytotoxic drugs on HbF and F cell production does not emerge from these studies, certain tentative conclusions can be drawn. First, it is certain that direct or indirect cytotoxicity Though transient reticulocytopenia regularly observed in this animal model is often not seen in patients with hemoglobinopathies who have been treated with these drugs, other differences such as effective dose and splenectomy effects on reticulocyte life span may be operative. Finally, it remains possible that S phase-specific drugs might cause gamma globin gene amplification. Indeed, exposure of certain cell lines to hydroxyurea can lead to gene amplification in a small subset of cells (23) . Dr. Stuart Orkin, Harvard Medical School, Boston, MA, has kindly examined the gamma globin region of the erythroblast DNA of these treated animals by restriction enzyme analysis and did not observe such amplification, but a small increase would be below the limits of detection in that system.
The stimulation of fetal hemoglobin production by cytotoxic drugs administered in vivo is the object of much interest because of obvious potential therapeutic implications, but it is important to recognize that it is not an isolated response. Hemoglobin A production decreases in concert with the rise in fetal hemoglobin. In short, a reversal of the fetal switch is seen. It is highly likely that other fetal erythroid characteristics will be observed as well, as is the case in "stress erythropoiesis" (24) . If such treatment is clinically successful, any of the effects on erythropoiesis may be responsible. The fetal hemoglobin response may simply be a marker and not the clinically effective result.
As these agents are carefully studied, it is very likely that their mechanisms of action, appropriate doses and scheduling, and the contributions of important interacting drugs will be determined. Evaluations of these treatments in simian models, as reported here and elsewhere (3, 4, 25) , are likely to provide important new concepts that will enhance their useful applications in the management of certain hemoglobinopathies, but determination of appropriate methods of administration will require cautious human trials.
